Inari Medical, Inc. (NASDAQ:NARI) Director Rebecca Chambers Sells 260 Shares

Inari Medical, Inc. (NASDAQ:NARI) Director Rebecca Chambers sold 260 shares of the business’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $45.99, for a total transaction of $11,957.40. Following the completion of the sale, the director now owns 9,684 shares in the company, valued at $445,367.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Rebecca Chambers also recently made the following trade(s):

• On Monday, May 20th, Rebecca Chambers sold 964 shares of Inari Medical stock. The stock was sold at an average price of $45.39, for a total transaction of $43,755.96.

Inari Medical Stock Performance

Shares of NASDAQ:NARI traded down $0.02 during midday trading on Monday, hitting $45.98. The company’s stock had a trading volume of 549,285 shares, compared to its average volume of 1,083,607. The business’s 50 day simple moving average is $44.44 and its 200 day simple moving average is $50.98. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $71.85.

Inari Medical (NASDAQ:NARI) last posted its quarterly earnings results on Tuesday, April 30th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.15). The business had revenue of $143.19 million during the quarter, compared to analysts’ expectations of $138.32 million. Inari Medical had a negative return on equity of 1.65% and a negative net margin of 4.54%. On average, sell-side analysts forecast that Inari Medical, Inc. will post -0.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inari Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Inari Medical by 11.1% during the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock worth $268,681,000 after purchasing an additional 561,562 shares during the last quarter. Brown Advisory Inc. increased its position in Inari Medical by 17.6% during the fourth quarter. Brown Advisory Inc. now owns 1,702,113 shares of the company’s stock worth $110,501,000 after purchasing an additional 255,182 shares during the last quarter. Bamco Inc. NY increased its position in shares of Inari Medical by 27.4% during the first quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock valued at $37,288,000 after acquiring an additional 167,000 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Inari Medical by 7.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 596,007 shares of the company’s stock valued at $38,693,000 after acquiring an additional 41,555 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Inari Medical by 23.4% during the fourth quarter. Principal Financial Group Inc. now owns 567,266 shares of the company’s stock valued at $36,827,000 after acquiring an additional 107,622 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NARI has been the subject of several recent analyst reports. Truist Financial reduced their price objective on shares of Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a research note on Friday, March 22nd. Needham & Company LLC cut their price target on shares of Inari Medical from $72.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Piper Sandler cut their price objective on shares of Inari Medical from $55.00 to $50.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 1st. Wells Fargo & Company lowered their price target on shares of Inari Medical from $100.00 to $84.00 and set an “overweight” rating on the stock in a report on Wednesday, May 1st. Finally, Canaccord Genuity Group lowered their price target on shares of Inari Medical from $75.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $65.71.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.